Oxytocin
Also known as: Pitocin, Syntocinon, Love hormone
Overview
Oxytocin is a 9-amino acid cyclic neuropeptide synthesized in the hypothalamus and released from the posterior pituitary. Colloquially known as the 'love hormone' or 'bonding hormone,' it plays key roles in social bonding, trust, sexual behavior, childbirth, and lactation. FDA-approved as Pitocin for labor induction and postpartum hemorrhage prevention, intranasal oxytocin is widely researched for social cognition enhancement in autism spectrum disorder, PTSD, anxiety, and as a potential cognitive and relationship enhancer.
Mechanism of Action
Oxytocin binds G-protein coupled oxytocin receptors (OTR) expressed in the brain (limbic system, amygdala, hippocampus, nucleus accumbens), uterus, mammary glands, and heart. Central OTR activation modulates social behavior, trust, fear extinction (via amygdala inhibition), and dopamine/serotonin release in reward circuits. Peripheral OTR activation drives uterine contractions and milk letdown. Intranasal administration delivers oxytocin to the brain via olfactory and trigeminal pathways, bypassing the blood-brain barrier.
Potential Benefits
- FDA-approved for labor induction and postpartum hemorrhage
- Enhanced social bonding and trust behaviors
- Fear extinction and anxiety reduction via amygdala modulation
- Improved social cognition in autism spectrum disorder studies
- Potential benefits in PTSD (enhancing fear memory extinction)
- Analgesic effects
- Cardioprotective effects in some models
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 10-40 IU nasal; 1-3 IU subcutaneous |
| Beginner | 10-20 IU intranasal as needed |
| Intermediate | 24-40 IU intranasal daily |
| Advanced | 40 IU intranasal; 3-5 IU subcutaneous for enhanced effect |
| Cycle Duration | As needed or 4-8 week structured courses |
| Cycle Off | 2-4 weeks if used daily; receptor downregulation possible with continuous use |
Intranasal oxytocin is the most studied non-invasive route for CNS effects (social behavior, anxiety, bonding). IV oxytocin used clinically for labor induction (10-40 mIU/min). Subcutaneous research doses extrapolated from clinical data.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic distribution
Most common administration route for research peptides. Inject into abdominal fat, thigh, or upper arm. Rotate sites. standard research dose.
Intramuscular Injection High — with slightly faster onset than SC
Alternative route when deeper delivery or faster absorption is desired. Less commonly used than SC for most research peptides.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Oxytocin:
Nootropic Stack
Combines Oxytocin with Semax (BDNF/cognition) and Selank (anxiolytic) for balanced cognitive enhancement and stress resilience.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 10 IU/ml nasal spray, 10 IU/ml injectable solution |
|---|---|
| BAC Water | Typically supplied pre-formulated in sterile saline |
| Storage | Refrigerate at 2-8°C; protect from light |
| Shelf Life | Typically 24 months unopened; follow manufacturer guidance for opened vials |
Need exact syringe measurements?
Amino Acid Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (disulfide bridge Cys1-Cys6)
Side Effects & Safety
- Uterine hyperstimulation (obstetric use risk)
- Water retention and hyponatremia
- Nausea
- Potential anxiety augmentation in some individuals
- Headache
- Intranasal: nasal irritation
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Bleeding Disorders
Active Skin Infection at Injection Site
FDA Safety Information
FDA labeling warns of uterine hyperstimulation, fetal distress, water intoxication, and hypotension when used for labor induction.
Pharmacokinetics
| Half-Life | ~3-5 minutes (IV/SC); ~20 min intranasal CNS effects |
|---|---|
| Storage | Injectable form: refrigerate at 2-8°C. Nasal spray: room temperature. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside Oxytocin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.